15 results about "Gain weight" patented technology

When fed to animals, Bacillus licheniformis strain O42AH3 (deposit accession number DSM 32559), Bacillus subtilis strain O52YJ6 (deposit accession number DSM 32560), Bacillus amyloliquefaciens strain O52YYT (deposit accession number DSM 32561) and / or Bacillus pumilis O72NR7 (deposit accession number DSM 32563) are useful for preventing and / or treating Lawsonia infections and for improving myriad performance parameters, including, but not limited to, body weight gain, average daily gain and feed conversion rates.

Described herein are compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, L1, T1, T2, T3, T4, t1, and t2 are defined herein; the use thereof as a GIPR antagonist; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts for the treatment or prevention of e.g. Obesity, weight gain and / or T2DM.

Use of an NLRP3 inhibitor for preventing and / or treating a disease or condition related to weight gain. Specifically, the present disclosure relates to use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating a disease or condition related to weight gain, wherein each substituent is as defined in the description.

The invention discloses a fatty acid chain for modifying a GLP-1 / GIP / glucagon receptor stimulant and application thereof, the fatty acid chain is used for modifying the receptor stimulant by improving the aspects of the carbon chain length, the functional group type and the like of the fatty acid chain, the treatment effect of the receptor stimulant on the aspects of reducing blood sugar and reducing body weight is remarkably improved, and the fatty acid chain can be used for modifying the GLP-1 / GIP / glucagon receptor stimulant. The fatty acid chain and the receptor agonist modified by the fatty acid chain can reduce the blood sugar level and improve the sugar tolerance; meanwhile, the effects of controlling appetite, ingestion and calorie intake, increasing energy consumption, preventing weight gain, promoting weight loss and reducing overweight are achieved; in addition, the fatty acid chain and the receptor agonist modified by the fatty acid chain have a long half-life period, and the action time of drugs in vivo can be effectively prolonged.

The present invention relates to a method for treating overweight, obesity, diabetes and / or related disorders, and / or for reducing body weight, by administering petrelintide at a high dose. The invention also relates to a method for treating overweight, obesity, diabetes and / or related disorders, and / or for reducing body weight, in a human female subject, by administering a non-incretin peptide hormone.

Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, A1, L1, L2, T1, T2, T3, T4, n1, t1, and t2 are defined herein; their use as GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and / or T2DM.

The present application relates to a kind of pharmaceutical composition, preparation and its preparation method and application, belong to the technical field of pharmaceutical preparation, at least to a certain extent, the deficiency of the curative effect and / or safety of existing single drug in treating non-alcoholic fatty liver disease combined with type 2 diabetes is solved.A kind of pharmaceutical composition, including berberine and FXR agonist, the mass ratio of berberine and FXR agonist is 1:5~5:1.The berberine and FXR agonist in the composition provided by the present application show high-efficiency synergistic effect under suitable compatibility, realize the reduction of efficiency, improve the safety of drug use and the compliance of patient, can also effectively inhibit weight gain, promote the biochemical index and weight of organism more tend to healthy state.

In this specification, compounds of formula I and their pharmaceutically acceptable salts (wherein R 1 , R 2 , R 3 , L 1 , T 1 , T 2 , T 3 , T 4 , t1, and t2 are as defined herein), their use as GIPR antagonists, pharmaceutical compositions containing such compounds and salts, and the use of such compounds and salts for treating or preventing, for example, obesity, weight gain, and / or T2DM are described. 【Chemical Formula 1】 TIFF2026516633000207.tif175168

Provided herein are stable aqueous pharmaceutical compositions and formulation comprising non-naturally occurring melanocortin antagonist analogs. The non-naturally occurring melanocortin antagonist analog comprises a sequence of Formula (I) Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 2), wherein c represents cyclization via a lactam bond.

The invention discloses a GLP-1 / GCG / GIP three-receptor agonist and an application thereof. By adjusting and optimizing the amino acid sequence of the receptor stimulant, the treatment effect on reducing blood sugar and reducing body weight can be remarkably improved, and the effect is better than that of tilpotide and retaglutide and is also better than that of other polypeptide compounds similar to the tilpotide and the retaglutide in structure; by improving the carbon chain length, the functional group type and the like of a fatty acid chain, the fatty acid chain is used for modifying a receptor agonist, the blood sugar level can be reduced, the sugar tolerance can be improved, and the effects of controlling appetite and calorie intake, increasing energy consumption, preventing weight gain and promoting weight loss are also achieved; the fatty acid chain modified receptor agonist has a long half-life period, can effectively prolong the action time of drugs in vivo, and can also be used for treating dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

The application belongs to the technical field of medicine, and particularly relates to application of a 4-(4-diethylamino-1-methylbutylamino)-7-chloroquinoline derivative or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or an internal racemate thereof, or an external racemate thereof, or an enantiomer thereof, or a diastereomer thereof, or a pharmaceutical composition with the active ingredient to preparation of a medicine for preventing or treating obesity and obesity-related metabolic diseases. The 4-(4-diethylamino-1-methylbutylamino)-7-chloroquinoline derivative has a significant curative effect on obesity and related metabolic diseases. After intragastric administration of the 4-(4-diethylamino-1-methylbutylamino)-7-chloroquinoline derivative to obese mice induced by high-fat feed and high-fructose drinking water, after 6 weeks, compared with a high-fat control group, the 4-(4-diethylamino-1-methylbutylamino)-7-chloroquinoline derivative inhibits more than 70% of weight gain of the mice, and there is no significant difference in food intake and water intake, and the 4-(4-diethylamino-1-methylbutylamino)-7-chloroquinoline derivative has a good clinical application prospect.

The invention belongs to the technical field of medicines, and particularly relates to a composition for preventing and treating children obesity and a preparation method thereof. The composition comprises the following raw materials in parts by weight: 35-45 parts of active pharmaceutical ingredients and 8-15 parts of auxiliary materials, the active pharmaceutical ingredient is composed of sipunculus nudus polypeptide and catalpa glycoside in a mass ratio of 1: (1.5-3). The composition can inhibit the weight gain of mice with high fat diet, reduce the total cholesterol, triglyceride and low-density lipoprotein level in serum of the mice, and improve the high-density lipoprotein level in the serum. In addition, the composition can also improve liver fat accumulation and relieve fatty liver lesion caused by liver fat accumulation, and has no influence on renal functions.

The present disclosure provides combinations for reducing weight and / or preventing weight gain in a subject (e.g., an obese subject) comprising three or more (e.g., three or four) of: (i) an amylin analog, (ii) a GLP-1 receptor agonist, (iii) a GIP analog, and (iv) a glucagon analog. As described herein, the combination can be administered to a subject in the same pharmaceutical composition or in separate pharmaceutical compositions (e.g., via concurrent or subsequent administration).

Provided is a method that involves inhibiting expression of UHRF1 in liver cells of an individual. Inhibiting the expression of UHRF1 promotes an inhibition of reduction of bone density or an increase in bone density, or inhibition of weight gain or a reduction in adipose mass, or inhibition of development of gray hair or an increase in activity level, or a decrease in biological age or enhanced liver regeneration, or increased survival following partial hepatectomy, or a combination of such effects.

Provided herein are methods of treating, preventing, reducing, or otherwise ameliorating one or more symptoms or conditions that may benefit from weight gain or a reduction in weight loss in a subject in need thereof. The methods comprise administering a non-naturally occurring melanocortin analog of the present technology to the subject.